Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 18,201 shares of the biopharmaceutical company’s stock after selling 99 shares during the period. PNC Financial Services Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $15,986,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. MCF Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the period. Criterion Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $37,000. Finally, Sutton Wealth Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 13 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the completion of the sale, the executive vice president now directly owns 37,543 shares of the company’s stock, valued at approximately $36,328,483.95. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the completion of the transaction, the executive vice president now owns 37,543 shares in the company, valued at approximately $36,328,483.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,925 shares of company stock worth $54,616,836. Corporate insiders own 8.83% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Bank of America lifted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Finally, UBS Group increased their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $989.36.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $993.95 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The firm’s 50 day simple moving average is $943.60 and its 200-day simple moving average is $912.25. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a market cap of $109.52 billion, a P/E ratio of 29.36, a price-to-earnings-growth ratio of 2.03 and a beta of 0.17.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.